AstraZeneca PLC (AZN)

121.95
-0.30(-0.25%)
  • Volume:
    762
  • Bid/Ask:
    121.65/122.80
  • Day's Range:
    121.60 - 123.05

AZN Overview

Prev. Close
122.25
Day's Range
121.6-123.05
Revenue
33.14B
Open
121.95
52 wk Range
97.86-137.3
EPS
1.32
Volume
762
Market Cap
188.18B
Dividend (Yield)
221.70
(1.95%)
Average Volume (3m)
468
P/E Ratio
100.01
Beta
0.213
1-Year Change
19.09%
Shares Outstanding
1,549,800,030
Next Earnings Date
-
What is your sentiment on AstraZeneca?
or
Market is currently closed. Voting is open during market hours.

AstraZeneca PLC News

AstraZeneca PLC Analysis

  • AZN Stock Under Pressure
    • ByTalkmarkets-

    Shares in UK-headquartered AstraZeneca are back under heavy selling pressure on Monday as the stock extends recent losses.

  • AstraZeneca’s Next “Wonder Drug”
    • ByTalkmarkets-

    Enhertu is an antibody-drug conjugate, a type of therapy designed to do minimal damage to healthy, non-cancerous cells. Wall Street analysts believe that Enhertu has the potential...

  • CinCor Pharma to be Acquired by AstraZeneca
    • ByTipRanks-

    WALTHAM, Mass., Jan. 09, 2023 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ: CINC) today announced that it has entered into a definitive agreement with AstraZeneca under which...

AstraZeneca PLC Company Profile

AstraZeneca PLC Company Profile

Employees
83100
  • Type:Equity
  • Market:Germany
  • ISIN:GB0009895292
  • WKN:886455

AstraZeneca PLC is a patient-focused pharmaceutical company. The Company focuses on discovery and development, manufacturing and commercialization of prescription medicines. The Company is focused on various therapy areas, such as Oncology; BioPharmaceuticals (comprising Cardiovascular, Renal & Metabolism (CVRM) and Respiratory & Immunology (R&I)), and Rare Disease. Its pipeline forms a robust portfolio of investigational therapies in various stages of clinical development. Its pipeline includes the Alexion Rare Disease portfolio and comprises approximately 177 projects, of which 161 are in the clinical phase of development. Its key marketed oncology products include Tagrisso (osimertinib), Lynparza (olaparib), Imfinzi (durvalumab), Koselugo (selumetinib), Farxiga/ Forxiga (dapagliflozin), Roxadustat, Onglyza (saxagliptin) and others. The Company’s geographical segments include United Kingdom, Rest of Europe, The Americas and Asia, Africa & Australasia.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellStrong SellStrong SellBuy
Technical IndicatorsSellStrong BuyBuyStrong SellStrong Buy
SummaryStrong SellStrong SellNeutralStrong SellStrong Buy
  • Double top in reach
    0